RESULTS ( 1 ) EQ-5D was valid and responsive for skin conditions and most cancers ; in vision , its performance varied according to aetiology ; and performance was poor for hearing impairments .
The HUI3 performed well for hearing and vision disorders .
It also performed well in cancers although evidence was limited and there was no evidence in skin conditions .
Response mapping using all the domain scores was the best performing model for the EORTC QLQ-C30 .
In an exploratory analysis , a limited dependent variable mixture model performed better than an equivalent linear model .
3 ) The exploratory valuation study found that bolt-on items for vision , hearing and tiredness had a significant impact on values of the health states , but the direction and magnitude of differences depended on the severity of the health state .
The vision bolt-on item had a statistically significant impact on EQ-5D health state values and a full valuation model was estimated .
EQ-5D performs well in studies of cancer and skin conditions .
Mapping techniques provide a solution to predict EQ-5D values where EQ-5D has not been administered .
For conditions where EQ-5D was found to be inappropriate , including some vision disorders and for hearing , bolt-ons provide a promising solution .
BACKGROUND The National Institute for Health and Care Excellence recommends the use of generic preference-based measures ( GPBMs ) of health for its Health Technology Assessment s ( HTAs ) .
However , these data may not be available or appropriate for all health conditions .
OBJECTIVES To determine whether GPBMs are appropriate for some key conditions and to explore alternative methods of utility estimation when data from GPBMs are unavailable or inappropriate .
( 2 ) Potential modelling approaches to ' map ' EQ-5D values from condition-specific and clinical measures of health [ European Organisation for Research and Treatment of Cancer Quality -of-life Question naire Core 30 ( EORTC QLQ-C30 ) and Functional Assessment of Cancer Therapy - General Scale ( FACT-G ) ] are compared for predictive ability and goodness of fit using two separate data sets . (
Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
OBJECTIVE To assess patient-reported outcomes ( PRO ) in patients with moderate-to-severe plaque psoriasis receiving continuous or paused etanercept treatment . METHODS In a multicentre European open-label study , one group ( n = 352 ) received continuous therapy : 25 mg subcutaneously ( SC ) twice weekly ( BIW ) throughout 54-weeks . The other group ( n = 359 ) received paused therapy : 50 mg SC BIW ( < or= 12 weeks ) until response was adequate by Physician Global Assessment ; after psoriasis returned , retreatment ( 25 mg BIW ) was begun . PRO included the Dermatology Life Quality Index ( DLQI ) , EuroQoL-5D ( EQ-5D ) , Hospital Anxiety and Depression Scale ( HADS ) , and the SF-36 Vitality subscale . RESULTS At baseline , mean DLQI for patients in the continuous ( 12.8 ) and paused group ( 13.8 ) , indicated significant quality -of-life impairment ; mean EQ-5D utility scores were 0.65 and 0.66 for continuous and paused patients , respectively ; 30.0 % of continuous and 37.0 % of paused patients had at least mild symptoms of depression ; 40.2 % and 48.6 % , respectively , had at least mild symptoms of anxiety . At week 54 , both groups showed statistically significant ( P < 0.05 ) and meaningful improvement in DLQI and EQ-5D scores ; improvements in HADS-D , HADS-A , and SF-36 vitality were also significant . Improvements in DLQI and EQ-5D were significantly greater in the continuous arm than the paused arm , but the differences were not meaningful . Differences between arms in HADS and SF-36 Vitality at week 54 were not significant . CONCLUSIONS At baseline , patients exhibited significant quality -of-life impairment . Both continuous and paused etanercept treatment provided improvements in PRO measures . Either regimen could be considered and care should be individualized
RESULTS ( 1 ) EQ-5D was valid and responsive for skin conditions and most cancers ; in vision , its performance varied according to aetiology ; and performance was poor for hearing impairments .
The HUI3 performed well for hearing and vision disorders .
It also performed well in cancers although evidence was limited and there was no evidence in skin conditions .
Response mapping using all the domain scores was the best performing model for the EORTC QLQ-C30 .
In an exploratory analysis , a limited dependent variable mixture model performed better than an equivalent linear model .
3 ) The exploratory valuation study found that bolt-on items for vision , hearing and tiredness had a significant impact on values of the health states , but the direction and magnitude of differences depended on the severity of the health state .
The vision bolt-on item had a statistically significant impact on EQ-5D health state values and a full valuation model was estimated .
EQ-5D performs well in studies of cancer and skin conditions .
Mapping techniques provide a solution to predict EQ-5D values where EQ-5D has not been administered .
For conditions where EQ-5D was found to be inappropriate , including some vision disorders and for hearing , bolt-ons provide a promising solution .
BACKGROUND The National Institute for Health and Care Excellence recommends the use of generic preference-based measures ( GPBMs ) of health for its Health Technology Assessment s ( HTAs ) .
However , these data may not be available or appropriate for all health conditions .
OBJECTIVES To determine whether GPBMs are appropriate for some key conditions and to explore alternative methods of utility estimation when data from GPBMs are unavailable or inappropriate .
( 2 ) Potential modelling approaches to ' map ' EQ-5D values from condition-specific and clinical measures of health [ European Organisation for Research and Treatment of Cancer Quality -of-life Question naire Core 30 ( EORTC QLQ-C30 ) and Functional Assessment of Cancer Therapy - General Scale ( FACT-G ) ] are compared for predictive ability and goodness of fit using two separate data sets . (